See more : CHK Oil Limited (0632.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Pacira BioSciences, Inc. (PCRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pacira BioSciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- African Gold Acquisition Corporation (AGAC-UN) Income Statement Analysis – Financial Results
- Earthstahl & Alloys Limited (EARTH.BO) Income Statement Analysis – Financial Results
- Legacy Housing Corporation (LEGH) Income Statement Analysis – Financial Results
- Asetek A/S (0QDT.L) Income Statement Analysis – Financial Results
- Euronext N.V. (ERNXY) Income Statement Analysis – Financial Results
Pacira BioSciences, Inc. (PCRX)
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 674.98M | 666.82M | 541.53M | 420.83M | 421.03M | 337.28M | 286.63M | 276.37M | 249.00M | 197.67M | 85.55M | 39.08M | 15.69M | 14.56M | 15.01M | 13.93M |
| Cost of Revenue | 184.67M | 199.30M | 140.26M | 117.33M | 106.71M | 86.85M | 87.92M | 110.10M | 71.84M | 77.44M | 54.77M | 32.14M | 16.74M | 12.28M | 12.30M | 17.46M |
| Gross Profit | 490.31M | 467.53M | 401.28M | 303.50M | 314.31M | 250.43M | 198.72M | 166.27M | 177.16M | 120.23M | 30.78M | 6.95M | -1.05M | 2.29M | 2.71M | -3.54M |
| Gross Profit Ratio | 72.64% | 70.11% | 74.10% | 72.12% | 74.65% | 74.25% | 69.33% | 60.16% | 71.15% | 60.82% | 35.98% | 17.77% | -6.69% | 15.70% | 18.03% | -25.41% |
| Research & Development | 76.26M | 84.80M | 55.55M | 59.42M | 72.12M | 55.69M | 57.29M | 45.68M | 28.66M | 18.73M | 21.56M | 9.94M | 14.87M | 18.63M | 26.23M | 33.21M |
| General & Administrative | 116.40M | 109.52M | 88.32M | 74.83M | 71.12M | 70.16M | 66.69M | 63.40M | 61.31M | 41.65M | 20.96M | 15.97M | 20.16M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 153.04M | 145.00M | 111.02M | 118.68M | 129.66M | 107.11M | 94.80M | 89.22M | 77.73M | 65.01M | 41.55M | 30.33M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 269.44M | 254.52M | 199.35M | 193.52M | 200.78M | 177.27M | 161.49M | 152.61M | 139.04M | 106.66M | 62.51M | 46.31M | 20.16M | 6.03M | 5.02M | 8.61M |
| Other Expenses | 56.94M | 57.29M | 13.55M | 7.87M | 5.70M | -888.00K | 167.00K | -82.00K | -165.00K | -159.00K | -47.00K | -111.00K | 3.02M | 6.03M | 5.02M | 8.61M |
| Operating Expenses | 402.63M | 396.60M | 268.44M | 260.80M | 278.60M | 232.95M | 218.78M | 198.29M | 167.71M | 125.39M | 84.07M | 56.24M | 35.03M | 24.66M | 31.25M | 41.83M |
| Cost & Expenses | 587.30M | 595.90M | 408.70M | 378.13M | 385.32M | 319.80M | 306.70M | 308.40M | 239.54M | 202.83M | 138.84M | 88.38M | 51.77M | 36.93M | 43.55M | 59.29M |
| Interest Income | 11.44M | 4.54M | 896.00K | 4.63M | 7.38M | 6.50M | 4.08M | 1.32M | 678.00K | 382.00K | 259.00K | 275.00K | 255.00K | 146.00K | 77.00K | 235.00K |
| Interest Expense | 20.31M | 39.98M | 31.75M | 25.67M | 23.63M | 21.95M | 18.05M | 7.06M | 7.73M | 8.28M | 7.25M | 1.81M | 4.78M | 4.89M | 3.60M | 3.49M |
| Depreciation & Amortization | 75.57M | 91.50M | 28.55M | 19.91M | 19.58M | 13.17M | 13.83M | 12.92M | 11.48M | 10.04M | 5.75M | 5.65M | 4.31M | 4.25M | 4.43M | 3.83M |
| EBITDA | 157.58M | 144.78M | 118.47M | 71.42M | 55.29M | 33.06M | -10.59M | -17.86M | 21.39M | 5.09M | -50.73M | -44.55M | -34.23M | -19.12M | -24.12M | -41.53M |
| EBITDA Ratio | 23.35% | 18.22% | 26.71% | 15.89% | 10.41% | 6.85% | -5.52% | -11.14% | 4.00% | -2.50% | -55.32% | -125.71% | -185.14% | -124.20% | -163.15% | -296.65% |
| Operating Income | 87.68M | 60.02M | 131.07M | 46.35M | 38.11M | 15.92M | -24.94M | -32.02M | 9.46M | -5.17M | -53.29M | -49.30M | -39.10M | -22.37M | -28.55M | -45.36M |
| Operating Income Ratio | 12.99% | 9.00% | 24.20% | 11.01% | 9.05% | 4.72% | -8.70% | -11.59% | 3.80% | -2.61% | -62.29% | -126.13% | -249.23% | -153.63% | -190.24% | -325.77% |
| Total Other Income/Expenses | -25.97M | -46.72M | -33.52M | -26.26M | -26.66M | -16.34M | -17.53M | -5.82M | -7.34M | -8.38M | -11.06M | -2.98M | -4.23M | -4.78M | -3.16M | 3.50M |
| Income Before Tax | 61.70M | 13.30M | 56.40M | 20.09M | -10.75M | -425.00K | -42.47M | -37.84M | 2.12M | -13.54M | -64.35M | -52.28M | -43.33M | -27.15M | -28.18M | -45.59M |
| Income Before Tax Ratio | 9.14% | 1.99% | 10.42% | 4.77% | -2.55% | -0.13% | -14.82% | -13.69% | 0.85% | -6.85% | -75.22% | -133.77% | -276.17% | -186.44% | -187.80% | -327.38% |
| Income Tax Expense | 19.75M | -2.61M | 14.42M | -125.43M | 268.00K | 46.00K | 140.00K | 105.00K | 264.00K | 173.00K | -442.00K | -3.95M | 7.25M | 4.78M | 3.16M | -3.50M |
| Net Income | 41.96M | 15.91M | 41.98M | 145.52M | -11.02M | -471.00K | -42.61M | -37.95M | 1.86M | -13.72M | -63.91M | -52.28M | -43.33M | -27.15M | -31.71M | -41.86M |
| Net Income Ratio | 6.22% | 2.39% | 7.75% | 34.58% | -2.62% | -0.14% | -14.87% | -13.73% | 0.75% | -6.94% | -74.70% | -133.77% | -276.17% | -186.44% | -211.30% | -300.62% |
| EPS | 0.91 | 0.35 | 0.95 | 3.41 | -0.27 | -0.01 | -1.07 | -1.02 | 0.05 | -0.39 | -1.93 | -1.72 | -2.64 | -1.58 | -55.32 | -79.23 |
| EPS Diluted | 0.81 | 0.34 | 0.92 | 3.33 | -0.27 | -0.01 | -1.07 | -1.02 | 0.04 | -0.39 | -1.93 | -1.72 | -2.64 | -1.58 | -55.32 | -79.23 |
| Weighted Avg Shares Out | 46.22M | 45.52M | 44.26M | 42.67M | 41.51M | 40.91M | 39.81M | 37.20M | 36.54M | 35.17M | 33.11M | 30.33M | 16.44M | 17.23M | 573.12K | 528.36K |
| Weighted Avg Shares Out (Dil) | 51.98M | 46.54M | 45.63M | 43.68M | 41.51M | 40.91M | 39.81M | 37.24M | 41.30M | 35.30M | 33.18M | 30.33M | 16.44M | 17.23M | 573.12K | 528.36K |
G.O.A.T. Bowl I Registration Open to 4 Additional Pickleball Teams
High Demand for Participation in Pickleball's Big Game on Feb. 9 in Las Vegas Leads to Tournament's Expansion to 24 Teams and Signing of New Sponsors LAS VEGAS , Feb. 1, 2024 /PRNewswire/ -- Paradise PB Events and G.O.A.T. Paddle,...
Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong
Pacira (PCRX) posts preliminary revenues for the fourth quarter and full year 2023.
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $675.0 million for the year ended...
Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
TAMPA, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference at 8:15 AM PT (11:15 AM EST) on Wednesday, January 10, 2024. Live...
20 favorite small-cap stocks for 2024 among Wall Street analysts
The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized companies have also rallied, but not as much:
Pacira Appoints Frank D. Lee as Chief Executive Officer
-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board --
Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion
The FDA approves Pacira's (PCRX) supplemental new drug application to expand the label of Exparel to include both sciatic and femoral nerve blocks.
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications
— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies —
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November
TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:
Pacira BioSciences, Inc. (PCRX) Q3 2023 Earnings Call Transcript
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Susan Mesco - Head of Investor Relations Dave Stack - Chairman & Chief Executive Officer Charlie Reinhart - Chief Financial Officer Conference...
Source: https://incomestatements.info
Category: Stock Reports